Aurora Cannabis unit gains EU-GMP certification

Aurora Cannabis Inc. reports that its wholly owned subsidiary Safari Flower Company has received European Union Good Manufacturing Practice (EU-GMP) certification for its Niagara Region, Ontario facility, granted for a three-year term.

Rhea-AI Filing Summary

Aurora Cannabis Inc. reports that its wholly owned subsidiary Safari Flower Company has received European Union Good Manufacturing Practice (EU-GMP) certification for its Niagara Region, Ontario facility, granted for a three-year term.

The 59,000 square foot cultivation and manufacturing site adds EU-GMP-certified capacity within Aurora’s global manufacturing network and supports supply of medical cannabis to international markets including Germany, Poland and the UK. Aurora notes that expectations about using this certification to meet global demand are forward-looking and subject to assumptions and risks described in its 2026 Annual Information Form.

Key Figures

EU-GMP certification term: three-year term Facility size: 59,000 square foot Safari acquisition timing: April 2026

3 metrics

EU-GMP certification term three-year term Duration of EU-GMP certification granted to Safari Flower Company's Ontario facility

Facility size 59,000 square foot Size of Safari's cultivation and manufacturing facility in the Niagara Region of Ontario, Canada

Safari acquisition timing April 2026 Month and year Aurora acquired Safari Flower Company to add EU-GMP capacity

Key Terms

European Union Good Manufacturing Practice, EU-GMP certification, forward-looking information, Annual Information Form

4 terms

European Union Good Manufacturing Practice regulatory

"receipt of European Union Good Manufacturing Practice ("EU-GMP") certification for its Ontario facility"

EU-GMP certification regulatory

"The achievement strengthens Safari's ability to serve international medical cannabis markets under the strictest regulations"

EU-GMP certification is an official approval that a drug or medical product maker follows the European Union’s Good Manufacturing Practice standards for consistent, safe production. For investors it signals lower regulatory and quality risk, smoother access to EU markets, and greater likelihood that products will pass inspections—similar to a restaurant earning a high food-safety grade showing reliable, repeatable processes.

forward-looking information regulatory

"This news release includes statements containing certain "forward-looking information" within the meaning"

Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.

Annual Information Form regulatory

"other risks as set out under "Risk Factors" contained in the Annual Information Form dated June 10, 2026"

A company's annual information form is a comprehensive regulatory filing that lays out its business description, key assets, risks, legal matters and other background details shareholders need to understand the company’s operations. Think of it as a detailed owner’s manual or dossier that supplements financial statements, helping investors do deeper homework on how the business works and what could affect its future performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aurora Cannabis (ACB) disclose about Safari Flower Company in this Form 6-K?

Aurora Cannabis Inc. disclosed that its wholly owned subsidiary Safari Flower Company received EU-GMP certification for its Niagara Region, Ontario facility for a three-year term. This confirms compliance with strict European manufacturing standards for supplying regulated international medical cannabis markets.

How long is Safari Flower Company’s EU-GMP certification valid according to Aurora Cannabis (ACB)?

Safari Flower Company’s EU-GMP certification is granted for a three-year term. During this period, the Niagara facility is recognized as meeting European Union Good Manufacturing Practice standards, supporting Aurora’s strategy to serve highly regulated international medical cannabis markets.

Where is Aurora Cannabis (ACB)’s EU-GMP-certified Safari facility located and how large is it?

Safari Flower Company operates a 59,000 square foot cultivation and manufacturing facility in the Niagara Region of Ontario, Canada. The newly confirmed EU-GMP status at this site underpins exports of medical cannabis to regulated international markets such as Germany, Poland and the UK.

How does the Safari Flower Company acquisition support Aurora Cannabis (ACB)’s global strategy?

Aurora acquired Safari Flower Company in April 2026 to add incremental EU-GMP capacity to its global manufacturing network. This acquisition is intended to support supply of high-quality medical cannabis to international markets that require rigorous quality, safety and compliance standards.

Which international markets does Aurora Cannabis (ACB) aim to serve through Safari’s EU-GMP facility?

Aurora highlights that Safari’s EU-GMP-certified facility will help supply medical cannabis to Germany, Poland and the UK. These are among the highly regulated international markets where EU-GMP compliance is critical for participation in medical cannabis supply chains.

What forward-looking risks does Aurora Cannabis (ACB) mention in connection with Safari’s certification?

Aurora notes that statements about using Safari’s EU-GMP certification to meet global demand are forward-looking and based on management assumptions. It points to numerous risks outlined under “Risk Factors” in its 2026 Annual Information Form, including regulatory, financing and operational uncertainties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/23/2026 - 07:40 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File No. 001-38691

AURORA CANNABIS INC. (Translation of registrant's name into English)

2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  ☐ Form 40-F  ☒

SUBMITTED HEREWITH

Exhibits		Description
99.1		News release dated July 23, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Miguel Martin

Miguel Martin
Chief Executive Officer

Date: July 23, 2026

Exhibit 99.1 

 

Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara Facility

The achievement strengthens Safari's ability to serve international medical cannabis markets under the strictest regulations

EDMONTON, AB, July 23, 2026 /CNW/ -- Safari Flower Company ("Safari"), a wholly owned subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), is proud to announce the receipt of European Union Good Manufacturing Practice ("EU-GMP") certification for its Ontario facility, solidifying its ability to serve international medical cannabis markets. The certification is granted for a three-year term and validates Safari Flower Company's unwavering commitment to meeting the highest international standards for quality, compliance and operational excellence.

 

Quote from Safari CEO, Brigitte Simons

"We are incredibly proud to achieve the highest level of EU-GMP certification, which reinforces our position as a trusted cultivator and manufacturer of high-quality medical cannabis for international markets," said Brigitte Simons, CEO of Safari Flower Company. "This milestone reflects the strong culture of compliance, quality and operational excellence embedded across our facility, and the trusted partnerships required to serve regulated supply chains. It further positions Safari to support the evolving needs of medical cannabis markets globally."

Safari's facility is a 59,000 square foot cultivation and manufacturing site in the Niagara Region of Ontario, Canada with a history of EU-GMP accreditations and exporting operations. Aurora acquired the Safari Flower Company in April 2026 to provide incremental EU-GMP capacity to align with the company's existing global manufacturing network and to support supply of high-quality medical cannabis to international markets including Germany, Poland, and the UK.

As international medical cannabis markets continue to evolve, EU-GMP certification remains a critical enabler of Safari's ability to serve regulated markets with confidence. The company is proud to be a trusted supplier of high-quality medical cannabis to markets that require rigorous quality, safety and compliance standards and to meet rapidly evolving patient demand.

About Safari Flower Company

Safari Flower Co. is a wholly owned subsidiary of Aurora Cannabis Inc., producing cannabis in the Niagara Region of Ontario, Canada. As a licensed operator, they are committed to producing safe medical products and enabling services to scale Canadian exports to international markets.

About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora^®, MedReleaf^®, Pedanios^®, IndiMed^™, San Raf^®, and Whistler Medical Marijuana Corporation^®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis^™.

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information 

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the EU-GMP certification of the Safari facility, Safari's and Aurora's ability to continue supporting the growing demand of highly regulated medical cannabis markets globally, Safari's and Aurora's commitment to meeting the highest international standards for quality, compliance and operational excellence, and the importance of EU-GMP to Safari's and Aurora's success.

Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion to revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other risks as set out under "Risk Factors" contained in the Annual Information Form dated June 10, 2026 (the "2026 AIF"). Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements. The Company cautions that the list of risks, uncertainties and other factors described in the 2026 AIF is not exhaustive and other factors could also adversely affect its results. Although the Company believes that the expectations conveyed by the forward-looking statements are reasonable based on the information available to the Company on the date hereof, no assurance can be given as to future results, approvals or achievements.

 

Safari Flower Co Logo

View original content to download multimedia:https://www.prnewswire.com/news-releases/safari-flower-company-a-wholly-owned-subsidiary-of-aurora-cannabis-receives-eu-gmp-certification-at-niagara-facility-302832821.html

SOURCE Aurora Cannabis Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2026/23/c9520.html

%CIK: 0001683541

For further information: For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com

CO: Aurora Cannabis Inc.

CNW 07:05e 23-JUL-26

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 NEWS RELEASE DATED JULY 23, 2026 12.2 KB